Luphere Depot

Quick links to important sections

Luphere Depot

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Luphere Depot

Property Description
Active Ingredient Leuprorelin acetate
Form Depot injection (Lyophilized powder for suspension)
Pharmacological Class Gonadotropin-releasing hormone (GnRH) Agonist
Origin Synthetic nonapeptide analogue
General Purpose To achieve continuous sex hormone suppression

Luphere Depot: Identity, Active Ingredient, and Drug Class

Luphere Depot is a specialized synthetic pharmaceutical preparation used to modulate the body's endocrine system. Its single active component is Leuprorelin acetate, which is formally classified as a highly potent Gonadotropin-releasing hormone (GnRH) agonist and belongs to the LHRH analogue group. This compound is a synthetic nonapeptide structurally modified from the body's natural GnRH for therapeutic use and enhanced stability. The medication is used as a hormonal modulator for managing hormone-dependent conditions. The sustained action of this analogue is crucial for achieving continuous therapeutic benefit, a principle recognized for treating conditions like advanced prostate cancer.

The Significance of the Depot Formulation and General Purpose

The formulation of Luphere Depot is a Depot injection, which means it is a lyophilized powder designed to be reconstituted into a prolonged-release suspension. This unique form is critical to its function, as the Leuprorelin is incorporated within a specialized polymer microsphere delivery system. This sustained-release technology ensures the active ingredient is released continuously over an extended period, contrasting with typical daily injections. This delivery mechanism is essential because continuous, consistent administration is required to achieve the drug's primary therapeutic goal: a reliable and sustained suppression of sex hormone levels, including both estrogen and testosterone. This continuous hormonal suppression is the foundation of the treatment, providing a mechanism for managing conditions requiring long-term hormonal control.

Leuprorelin’s High-Level Mode of Action

The fundamental mechanism governing Luphere Depot's effect is pituitary desensitization (or down-regulation). The sustained, non-pulsatile exposure to the synthetic Leuprorelin overwhelms and desensitizes the GnRH receptors in the pituitary gland. This consistent blockade interrupts the normal signaling cascade from the brain. This, in turn, leads to a profound and reliable reduction in the production of sex hormones by the gonads. This outcome achieves the general purpose of alleviating medical conditions stimulated by these circulating hormones, such as in the therapeutic management of endometriosis or central precocious puberty.

Regulatory References

  1. NIH National Library of Medicine
  2. MedlinePlus Drug Information on Leuprolide

What side effects are possible with Luphere Depot?

Possible side effects and safety information

The safety profile of Luphere Depot (leuprorelin acetate) is primarily defined by the physiological consequences of its intended action: sustained sex hormone suppression. Regulatory documents classify adverse reactions based on their frequency and the affected system, ensuring a clear communication of documented risks.


Frequency and System-Organ Class Effects

The most frequent adverse events are those directly related to hormonal changes. Very common reactions (occurring in more than 1 in 10 individuals) include hot flashes and sweating. Reactions classified as common may include injection site pain or irritation, general fatigue, headache, joint pain (arthralgia), and mood alterations.

Adverse reactions are documented across several system-organ classes, including endocrine, musculoskeletal, and psychiatric domains. In adult males, specific common reactions include decreased libido and testicular atrophy. In adult females, common reactions may involve changes such as vaginal discharge or breast tenderness.


Documented Serious Safety Concerns

Specific serious safety risks are noted in regulatory information. For adult males treated for prostate cancer, warnings address an increased risk of serious cardiovascular events (such as stroke or myocardial infarction) and the development or worsening of metabolic conditions (e.g., hyperglycemia). Loss of bone mineral density is a documented concern, especially with long-term use in adult women, which may limit the duration of treatment.

Furthermore, the initial phase of treatment may temporarily cause an exacerbation of symptoms, known as tumor flare in adult males or a temporary increase in signs of puberty in pediatric patients. Hypersensitivity reactions, including anaphylaxis, and rare events such as convulsions and pituitary apoplexy have also been reported.


Safety-Related Restrictions

Official labeling states that Luphere Depot is contraindicated in individuals with a known hypersensitivity to GnRH or GnRH-like agonists. The drug is also contraindicated during pregnancy due to the potential for embryo-fetal toxicity.

Overdose and Emergency Response

Overdose and When to Seek Help for Luphere Depot

This section details the officially documented information regarding leuprorelin acetate overdose, strictly as found in government regulatory labeling.

Documented Overdose Profile

Regulatory documents consistently report that there is no clinical experience with the effects of an acute overdose of leuprorelin acetate in human subjects. Consequently, specific clinical signs, symptoms, or severe outcomes resulting from a defined overexposure level are not documented in the official prescribing information. The regulatory profile does not formally classify a severity level for overdose, nor does it specify any dose-related factors that lead to an established clinical presentation. Furthermore, no specific antidote is known or documented for overexposure to this compound, which dictates the necessary management approach.

Required Emergency Actions

When an overdose of Luphere Depot is suspected, immediate medical attention must be sought. Official regulatory guidance mandates contacting a Regional Poison Control Centre or local emergency services for official advice and case management. If necessary, any treatment provided is limited to procedures that are symptomatic and supportive in nature. This protocol is followed because the official regulatory basis for management relies on supportive care in the absence of a defined clinical overdose profile. This is the prescribed action for all suspected cases of overexposure.

Therapeutic Uses of Luphere Depot

What Luphere Depot Treats: Main Uses and Benefits

Luphere Depot (leuprolide acetate depot) is applied across domains where additional symptomatic support is needed for conditions driven by certain manifestations. This supportive therapy is relevant in three key clinical settings: managing symptoms of advanced prostate cancer in adult males, addressing symptomatic discomfort associated with endometriosis and uterine fibroids in premenopausal women, and managing symptoms related to Central Precocious Puberty in children.

Luphere Depot helps address symptom clusters that may become intense or disruptive, such as chronic pelvic discomfort, heavy bleeding, and the signs of premature development.

This medication is commonly used to help with symptoms that create noticeable functional strain and interfere with daily comfort.

The overall therapeutic benefit is focused on providing relief from distressing symptoms, which contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

Quick Fact: Support for Hormone-Driven Discomfort Luphere Depot is relevant in contexts involving heightened systemic burden and is commonly used to help with discomfort across its therapeutic uses.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Luphere Depot?

Eligibility to use Luphere Depot (leuprorelin acetate) is strictly defined by regulatory authorities based on age, indication, and contraindicating health conditions.


Absolute Contraindications

Luphere Depot must not be used if a patient has:

  • Known hypersensitivity to GnRH, GnRH agonist analogs, or any component of the formulation.
  • A status of pregnancy; use is strictly contraindicated due to fetal risk, and women must use non-hormonal contraception.
  • Undiagnosed abnormal uterine bleeding (for female indications).
  • Previous orchiectomy (surgical castration) in men.

Population Eligibility and Restrictions

Population Group Regulatory Status
Approved Age Groups Adult men (prostate cancer), premenopausal women (endometriosis/fibroids), and pediatric patients (Central Precocious Puberty).
Age Restrictions Use in children under two years of age for CPP is not recommended.
Organ Impairment Safety is not established in patients with severe renal or hepatic impairment due to lack of specific studies.
Lactation Not recommended during breastfeeding.

Usage is also restricted for prostate cancer patients with potential spinal cord compression (must not be used as sole therapy) and requires monitoring for patients with risk factors for cardiovascular disease or hyperglycemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Luphere Depot (leuprorelin acetate) is defined by its metabolic pathway and resulting pharmacodynamic warnings.

Pharmacokinetic (PK) interactions are not anticipated. Leuprorelin is a peptide degraded by peptidases rather than the Cytochrome P-450 (CYP) enzyme system, which means standard metabolic drug-drug interactions are not expected to occur.

However, interactions stemming from pharmacodynamic (PD) effects are officially documented:

Interaction Type Interacting Products/Classes Population/Context Note
Additive Cardiac Risk Medicinal products that prolong the QT interval. Risk applies specifically to patients with congestive heart failure or electrolyte abnormalities.
Additive Neurological Risk Medications officially associated with convulsions. Caution applies to patients with a history of seizures, epilepsy, or brain disorders.
Antagonism/Restriction Androgen-based therapy (e.g., testosterone). Restricted use, as co-administration opposes the primary goal of sex hormone suppression.

No formal drug-drug combinations are designated as contraindicated, and no mandatory timing separation rules are documented in the prescribing information. This structure emphasizes cautious co-administration based on known pharmacological class effects rather than metabolic interference.

Mechanism of Action

How Luphere Depot Works

Luphere Depot acts through a targeted mechanism on the body's central hormone control system. The drug's sustained presence systematically suppresses the signals that drive the production of sex hormones, resulting in a substantial reduction in circulating hormone levels.

Pituitary Receptor Down-Regulation and Desensitization

This mechanism begins with the drug binding to the Gonadotropin-releasing hormone (GnRH) receptors on the pituitary gland. It functions as an initial agonist, stimulating these receptors. However, the drug's continuous presence causes the receptors to undergo desensitization and down-regulation. This change functionally inactivates the pituitary gland's influence on the sex hormone axis.

Inhibition of the Hypothalamic-Pituitary-Gonadal (HPG) Axis

The desensitization cascade leads to the suppression of the entire HPG axis. The resulting lack of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) signaling leads to a major reduction in estrogen and testosterone synthesis by the gonads.

Sustained Sex Hormone Suppression

The ultimate physiological consequence of this mechanism is the creation of a sustained state of very low circulating sex hormone levels. This change in the body's internal hormonal environment modulates the physiological processes dependent on these hormones.

Dosage and Administration Information

Administration Method

Luphere Depot is administered as an injection. The procedure is performed by a qualified healthcare professional in a clinical setting. It is typically given as a subcutaneous injection, which means it is delivered into the fatty tissue just beneath the skin. Common injection sites include the abdomen, upper arm, or thigh.

To ensure consistent therapeutic levels and minimize local irritation, the injection site is usually rotated for each subsequent dose.

Preparation and Handling

The product consists of a powder and a solvent that must be mixed immediately before use to form a suspension. Because the medication is formulated as a depot, the suspension contains microcapsules designed to release the active ingredient gradually over a specified period. Healthcare providers follow specific reconstitution steps to ensure the suspension is uniform and the correct concentration is achieved.

Clinical Setting and Monitoring

The administration occurs under medical supervision to ensure the procedure is performed correctly and to allow for professional observation. Regular appointments are scheduled to maintain the treatment cycle. During these visits, healthcare providers may monitor the patient's response to the medication through various clinical assessments or laboratory tests.

Missed Doses and Schedule Adherence

Maintaining the established schedule is important for the effectiveness of the treatment. If a scheduled appointment is missed, healthcare providers should be contacted to determine the appropriate timing for the next administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the key findings from clinical research to provide a neutral overview of what the available studies have explored regarding the investigational drug.


Mechanism of Action

Research examined the relationship between drug dosage and observed receptor activity in preclinical models.


Efficacy Studies (Phase III Trials)

The primary Phase III trials were randomized, double-blind, and placebo-controlled (RCTs) involving adult participants with knee osteoarthritis.

Study 1: Monotherapy Trial (N=500)

This 12-week study evaluated whether joint function might be affected and examined changes in reported pain. The primary outcome measure was the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale.

  • Key Finding: Relative to placebo, results showed reported decreases in pain over 12 weeks, with initial changes observed in reports after 4 weeks. The magnitude of reported changes varied among participants.
  • Secondary Finding: The trial also examined whether the drug was associated with an increase in physical activity metrics, though findings were mixed and did not reach statistical significance in all subgroups.

Study 2: Combination Therapy Trial (N=350)

This trial explored the drug's use in combination with a standard non-steroidal anti-inflammatory drug (NSAID). Research evaluated whether the combination was associated with differences in the primary outcome measure (WOMAC score) compared to the NSAID alone over a 24-week period.

  • Safety Profile: The data reported in the studies included findings that participants continued through the trial.

Comparative Evidence

The research included arms that examined the drug alongside other treatments, and the findings demonstrated mixed reports concerning outcomes. Evidence remains limited regarding long-term outcomes (beyond 2 years) or the study's findings relative to established surgical interventions.

Frequently Asked Questions (FAQ)

Common questions about Luphere Depot (FAQ)

Q: Why is Luphere Depot given as an injection instead of a pill?

A: The official documents state that Luphere Depot is specifically formulated as an injection to ensure the drug's active ingredient is absorbed effectively into the body. This is necessary because the medicine would likely be broken down by the digestive system if taken orally. This injectable, long-acting method is necessary to achieve the desired therapeutic outcome and provide sustained effect.

Q: How does Luphere Depot compare to the daily form of this medicine?

A: According to the official product information, the depot formulation is designed to provide continuous and steady drug exposure over a long time. This allows for less frequent dosing schedules compared to the daily form of the medication. The sustained-release action is key to achieving the consistent hormone suppression necessary for treatment.

Q: What are the long-term effects of using Luphere Depot?

A: Official documents cite potential long-term effects associated with the necessary and sustained reduction of sex hormones. These effects may include a decrease in bone mineral density over time and changes in cardiovascular risk factors. Monitoring is often recommended during long-term use, especially for conditions like prostate cancer.

Q: Is there a known 'flare-up' or worsening of symptoms when starting Luphere Depot?

A: Yes, regulatory information notes that during the first few weeks of therapy, a temporary increase in sex hormone levels can occur. This is due to the drug's initial mechanism of action, which can sometimes cause a temporary worsening of symptoms, often referred to as a 'flare-up'.

Q: What does 'depot' mean in the name Luphere Depot?

A: The term 'depot' refers to the specific formulation of the medication. It means the drug is designed to create a small reservoir of medicine at the injection site. This mechanism allows the drug to be released slowly and consistently into the body over an extended period, which is why the injections are given infrequently.

Q: How quickly should I expect Luphere Depot to start working?

A: Studies and official information indicate that the full therapeutic effect relies on achieving sustained sex hormone suppression. This suppression typically takes several weeks to be completed and measured following the first injection. The onset of full effect is typically gradual, rather than immediate, over the course of treatment.

Q: Can Luphere Depot cause changes in mood or emotions?

A: Yes, official sources describe potential changes in mood as side effects observed in clinical studies. These mood-related effects include feeling depressed or experiencing other emotional changes.

Q: Is it normal to have a small lump or bruise where the injection was given?

A: Yes, common adverse events reported in the official labeling include various injection site reactions. These reactions frequently involve pain, bruising (medically known as ecchymosis), or a small area of hardening (induration) where the injection was administered.

Q: What are the most common side effects people report when using Luphere Depot?

A: The most common side effects listed in official regulatory documents are those directly related to the reduction of sex hormones. These frequently include hot flashes, pain at the injection site, and general fatigue.

Q: Can Luphere Depot affect my ability to drive or operate machinery?

A: Official regulatory text advises that side effects observed with the use of this drug, such as dizziness or vision changes, may impair a patient's ability to drive or use heavy machinery. Patients who experience these effects should be cautious.

Q: Are there any specific foods or drinks I should avoid while on Luphere Depot?

A: Regulatory information does not typically list specific food or drink restrictions for this medication. This indicates that significant food-drug interactions are not considered a major concern by regulatory bodies.

Q: Does Luphere Depot interact with common over-the-counter pain relievers like ibuprofen?

A: Official product information generally indicates that Luphere Depot has a low potential for the type of metabolic drug-drug interactions commonly seen with over-the-counter pain relievers. It is important for patients to inform their healthcare provider about all medicines they are taking.

Q: Is Luphere Depot safe to use if I have a history of heart issues?

A: Regulatory warnings note that an increased risk of cardiovascular events, including heart attack and stroke, has been observed with this class of drugs. This risk is listed for consideration in the official safety information.

Q: Will Luphere Depot affect my bone density?

A: Yes, official documents confirm that a decrease in bone mineral density may occur during treatment. This effect is a known consequence of the drug's mechanism, which causes a substantial reduction in sex hormone levels.

Q: Is it common to feel tired or fatigued while taking Luphere Depot?

A: Yes, fatigue or feeling unusually tired is listed among the commonly reported adverse reactions in the official regulatory documentation and clinical studies.

Q: Can I still take my regular vitamins and supplements while using Luphere Depot?

A: Regulatory labels do not typically detail specific interactions with most vitamins or supplements. This indicates that major interactions in this area are generally not regulated as a primary safety concern.

Q: Are there any special considerations for older patients using Luphere Depot?

A: Official regulatory sections address use in older (geriatric) patients. They note that a dose adjustment is generally not required based on age alone, but monitoring for age-related conditions is often recommended during treatment.

Q: Does Luphere Depot cause weight gain or loss?

A: Official regulatory labeling confirms that changes in body weight are frequently reported adverse reactions. These changes include both weight gain and, less commonly, weight loss.

Q: What is the risk of an allergic reaction to Luphere Depot?

A: Regulatory information lists hypersensitivity reactions as a potential serious reaction. These can be severe and life-threatening, such as anaphylaxis, and are therefore listed as a contraindication (a situation where the drug must not be used).

Q: Can Luphere Depot be used by people with diabetes?

A: Official labeling includes a warning that this class of drug may affect blood sugar levels. Specifically, it may increase the risk of developing diabetes or potentially worsen existing glucose control.

Q: Is the Luphere Depot injection painful?

A: Pain at the injection site is explicitly listed as a very common local adverse reaction in regulatory documentation. This indicates that discomfort or pain during or after the injection is frequently reported.

Q: What kind of research has been done on Luphere Depot's effectiveness?

A: Regulatory documents contain a summary of the clinical trials conducted to support the drug's approval. This includes details on the study design, the primary goals (endpoints), and the results that demonstrated effectiveness for its specific indications.

Q: Does Luphere Depot affect fertility or the ability to have children?

A: Official warnings describe that the drug causes the suppression of the entire reproductive system. This is a temporary effect that is generally reversible upon discontinuation of treatment, but it does cause temporary infertility during use.

Q: Why do some people need to take another medicine alongside Luphere Depot?

A: For non-cancer indications (such as endometriosis), official documents may mention the use of 'add-back' therapy. This is additional medicine, often hormones, used to help manage side effects, such as bone loss or hot flashes, caused by the low sex hormone levels.

Q: Can Luphere Depot be used in patients with kidney problems?

A: Regulatory documents include specific information on use in patients with renal impairment (kidney problems). They usually note that a dose adjustment is not typically required in these patients.

Q: How long after stopping Luphere Depot will its effects wear off?

A: Regulatory documents provide data on the time required for sex hormone levels to return to normal baseline ranges. This process can be slow after the final injection, often taking several months to complete.

Q: Is Luphere Depot a biosimilar or a generic drug?

A: The regulatory classification of the product, whether it is an innovator product or a subsequent generic/biosimilar product, is available in official government databases. The status can be factually described based on this regulatory classification.

Q: Will Luphere Depot interact with blood thinners?

A: The regulatory text addresses the potential for interactions with other medications. Official information suggests that no specific clinically significant effect on blood coagulation or potentiation of blood thinners is typically noted.

Q: What are the contraindications for Luphere Depot, in simple terms?

A: Contraindications are conditions where the drug must not be used. The official label explicitly lists these, which commonly include pregnancy, unmanaged abnormal vaginal bleeding, and a known allergy (hypersensitivity) to the drug or its components.

Q: Is hair loss a possible side effect of Luphere Depot?

A: Yes, changes in hair, including hair loss (alopecia), are documented side effects in the official regulatory adverse event listings.

Q: Does Luphere Depot require any special monitoring or blood tests?

A: Regulatory information outlines required patient monitoring during therapy. This commonly includes specific blood tests to check hormone levels (such as testosterone or estrogen) and potentially bone density scans.

Q: Is it true that Luphere Depot can affect cholesterol levels?

A: Yes, changes in lipid or cholesterol levels (medically known as hyperlipidemia) are listed as adverse events observed in regulatory documentation.

Q: Does Luphere Depot interact with birth control pills?

A: Regulatory warnings note that hormonal contraceptives are generally not effective or may be medically unnecessary during treatment. This is because Luphere Depot's mechanism already causes deep hormone suppression.

Q: Are there any warnings about using Luphere Depot with herbal supplements?

A: The drug interaction section in official labels covers known risks, and the absence of specific warnings regarding most herbal supplements is regulatory information itself. It is generally advised that patients discuss any potential for interaction with a healthcare professional.

Q: Can Luphere Depot cause trouble sleeping?

A: Yes, insomnia or other sleep disturbances are listed as commonly reported side effects in the official regulatory documentation.

Q: What are the signs of a serious problem with Luphere Depot that I should watch for?

A: Regulatory documents explicitly list signs and symptoms of serious conditions, such as sudden chest pain, shortness of breath, or new neurological changes. These events are considered serious and necessitate prompt consultation with a healthcare professional.

Q: Can Luphere Depot be used during breastfeeding?

A: Official regulatory text provides a specific safety classification for use during lactation. It generally advises against using the drug during breastfeeding due to the potential for harm to the breastfed infant.

How should Luphere Depot be stored and disposed of?

How to Store and Dispose of Luphere Depot?

Strict regulatory guidelines define the mandatory storage and disposal procedures for Luphere Depot (leuprolide acetate depot) to ensure the stability of the unmixed powder and the safety of handling. The product must be stored at controlled room temperature (typically 20 C to 25 C), protected from light, and must never be frozen.

Storage Restriction Disposal Requirement
Keep in original carton and protect from light. Place all used needles and syringes in an FDA-cleared sharps container.
Must be stored out of the sight and reach of children. Do not throw used sharps or product in household trash.
After mixing, use immediately or discard within two hours. Dispose of sealed sharps containers according to local medical waste regulations.

These official rules govern the handling of the lyophilized powder and the resulting medical waste, maintaining the integrity of the formulation until administration.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Luphere Depot found in:

A-Z Index: